PHASE 1/2 TRIAL OF ANDROGEN DEPRIVATION, WITH OR WITHOUT PTVG-AR AND WITH OR WITHOUT NIVOLUMAB, IN PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK PROSTATE CANCER
$3,082,636FY2021Defense Health AgencyDOD
University Of Wisconsin System, Madison WI
University Of Wisconsin System, Madison WI